Regulatory T cells from patients with end-stage organ disease can be isolated, expanded and cryopreserved according good manufacturing practice improving their function

Francesca Ulbar1†, Tiziana Montemurro2†, Tatiana Jofra3, Miriam Capri4, Giorgia Comai5, Valentina Bertuzzo6, Cristiana Lavazza2, Alessandra Mandelli3, Mariele Viganò2, Silvia Budelli2,7, Maria Giulia Bacalini8, Chiara Pirazzini9, Paolo Garagnani4,9,10,11,12, Valeria Giudice13, Daria Sollazzo1, Antonio Curti3, Mario Arpinati1, Gaetano La Manna3, Matteo Cescon6, Antonio Daniele Pinna6, Claudio Franceschi8, Manuela Battaglia3, Rosaria Giordano2, Lucia Catani1*† and Roberto Massimo Lemoli13,14,15†

Abstract

Background: Here, we isolated, expanded and functionally characterized regulatory T cells (Tregs) from patients with end stage kidney and liver disease, waiting for kidney/liver transplantation (KT/LT), with the aim to establish a suitable method to obtain large numbers of immunomodulatory cells for adoptive immunotherapy post-transplantation.

Methods: We first established a preclinical protocol for expansion/isolation of Tregs from peripheral blood of LT/KT patients. We then scaled up and optimized such protocol according to good manufacturing practice (GMP) to obtain high numbers of purified Tregs which were phenotypically and functionally characterized in vitro and in vivo in a xenogeneic acute graft-versus-host disease (aGVHD) mouse model. Specifically, immunodepressed mice (NOD-SCID-gamma KO mice) received human effector T cells with or without GMP-produced Tregs to prevent the onset of xenogeneic GVHD.

Results: Our small scale Treg isolation/expansion protocol generated functional Tregs. Interestingly, cryopreservation/thawing did not impair phenotype/function and DNA methylation pattern of FOXP3 gene of the expanded Tregs. Fully functional Tregs were also isolated/expanded from KT and LT patients according to GMP. In the mouse model, GMP Tregs from LT or KT patient proved to be safe and show a trend toward reduced lethality of acute GVHD.

Conclusions: These data demonstrate that expanded/thawed GMP-Tregs from patients with end-stage organ disease are fully functional in vitro. Moreover, their infusion is safe and results in a trend toward reduced lethality of acute GVHD in vivo, further supporting Tregs-based adoptive immunotherapy in solid organ transplantation.

Keywords: End stage organ disease, Regulatory T cells, Safety, Murine model

*Correspondence: lucia.catani@unibo.it
†Francesca Ulbar, Tiziana Montemurro, Lucia Catani and Roberto Massimo Lemoli contributed equally to this work
1 Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology “L. e A. Seràgnoli”, University of Bologna, Bologna, Italy

Full list of author information is available at the end of the article

© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Organ transplantation is the only curative treatment for patients affected by end-stage liver or kidney disease. Although immunosuppressive (IS) drugs have reduced the incidence of acute rejection and transplantation-associated mortality, their administration is associated with major side effects, such as opportunistic infections, damage of transplanted organs and secondary cancer [1, 2]. Therefore, new strategies to improve long-term graft survival while reducing/eliminating IS therapy and, ideally, inducing immunological tolerance are needed.

Cellular therapy can improve the outcome of solid organ transplantation through anti-inflammatory effects and the induction of immune tolerance. T cell-mediated immunomodulation is one of the main mechanisms to maintain operational tolerance (withdrawal of immunosuppressive drugs while maintaining normal graft function and histology) in vivo. It is now accepted that regulatory T cells (Tregs), a subpopulation of T helper lymphocytes, are responsible for this immunomodulatory activity, as a result of their suppressive effects directly on effector T cells and on antigen presenting cells [3, 4]. Circulating Tregs constitutively express CD25 and FoxP3 and represent 5–10% of all peripheral CD4+ T cells [5, 6]. Tregs, which are fundamental for the maintenance of immune homeostasis, demonstrated a key role for transplantation tolerance in animal models by impairing the function of CD8+ T cells [7–10]. In humans, cell therapy with human Tregs for the induction of transplantation tolerance represents a promising strategy [10, 11]. Indeed, clinical trials using this approach have already demonstrated that expanded polyclonal and antigen-specific Tregs are safe and effective in the treatment of GVHD and Type 1 diabetes [12–17]. Conversely, very few results have been published on clinical trials testing the efficacy of Tregs in solid organ transplantation [18, 19]. Moreover, isolated/ex vivo expanded Tregs have been only tested in animal models [20–22].

Here, we first established a preclinical protocol for expansion/isolation of Tregs from patients with end-stage liver or kidney disease being in the waiting list for liver/kidney transplantation (LT/KT). We then scaled up and optimized such protocol according to good manufacturing practice (GMP) to obtain high numbers of purified Tregs which were tested in vitro and in a xenogeneic acute graft-versus-host disease (GVHD) mouse model.

Materials and methods
Patients
Peripheral blood (20–60 mL) was obtained from 14 LT and 9 KT patients. Patients characteristics are outlined in Table 1. Patient selection for GMP Tregs isolation/expansion was based on the following inclusion criteria: (1) age ≥ 18 years; (2) diagnosis of end-stage kidney disease in waiting list for living donor kidney transplantation or diagnosis of end-stage liver disease in waiting list for liver transplantation. Exclusion criteria included: (1) HIV, HBV, HCV positivity; (2) syphilis antibody positivity; (3) combined transplant; (4) concurrent uncontrolled infection. Patient selection for in vitro experiments were as above described except virus positivity. Peripheral blood (20–60 mL) and buffy-coat (30 mL) were also obtained from age and sex matched healthy controls. Human studies were conducted in accordance with the Declaration of Helsinki and approved by the local ethical Committee (232/2015/O/Tess by Investigation Drug Service, Azienda Ospedaliero-Universitaria di Bologna). Informed consent was obtained from all the subject prior to enrollment into the study.

Circulating Treg enumeration
Enumeration by flow cytometry of circulating Treg (CD4+CD25+CD127–FoxP3+) was carried out in the peripheral blood (PB) of selected KT and LT patients (n = 7 and n = 10, respectively) and of healthy controls (n = 9). The conjugated monoclonal antibodies used are shown in Additional file 1: Table S1. Surface marker staining was performed for 15 min at room temperature. For intracellular staining, anti-human FoxP3 (PCH101) Staining Set PE Kit was used (eBiosciences), according to the manufacturer’s instructions. Isotype control rat IgG2 PE was used as a control. Briefly, cells were stained for surface markers CD4, CD25 and CD127, washed once in PBS and then fixed/permeabilized. After washing, cells were incubated with anti-human FoxP3 antibody for 30 min at 4 °C in the dark. A lysis buffer (Becton–Dickinson) was used in order to lysate red blood cells. The phenotype of Tregs was analyzed by flow cytometry.

Table 1 Patients characteristics

|                  | KT   | LT   | CTR  |
|------------------|------|------|------|
| Total number     | 9    | 14   | 10   |
| Sex (male/females) | 3/6  | 8/6  | 5/5  |
| Age (years; mean ± SD) | 53 ± 13 | 61 ± 10 | 58 ± 12 |
| Disease          |      |      |      |
| HCV/HBV liver cirrhosis | N = 0 | N = 8 | NA   |
| Alcoholic liver cirrhosis | N = 0 | N = 3 | NA   |
| Dysmetabolic liver cirrhosis | N = 0 | N = 2 | NA   |
| Cryptogenetic liver cirrhosis | N = 0 | N = 1 | NA   |
| Epatorenal polycystic disease | N = 4 | N = 0 | NA   |
| End stage kidney disease | N = 4 | N = 0 | NA   |
| Drug-induced tubulointerstitial nephritis | N = 1 | N = 0 | NA   |

NA not applicable, LT liver transplant, KT kidney transplant, CTR healthy control.
Tregs isolation and expansion
EDTA-anticoagulated peripheral blood (60 mL) was collected from 4 LT patients, 2 KT patients and buffy-coat (30 mL) from 5 controls. Peripheral blood mononuclear cells (PBMC) were then isolated by Ficoll-Hystopaque density gradient centrifugation.

Isolation: freshly isolated CD8−CD25+ T cells were purified from PBMC by negative selection of CD8+ T cells followed by positive selection of CD25+ T cells using specific Miltenyi-Biotec beads (CD8 microbeads human and CD25 microbeads II human) with Midi-MACS separator and a purity (CD4+CD25+) of > 90%.

Expansion: freshly isolated cells were plated at 1 × 10⁶/mL cells and activated with anti-CD3/CD28 coated beads (Invitrogen, Paisley, UK; Miltenyi Biotech) at a 4:1 bead:cell ratio at day 0 and then 1:1 bead:cell ratio weekly. Cells were expanded in culture media (TECSMacs GMP medium, Miltenyi Biotec) 5% human AB plasma containing rapamycin (100 nM) (Rapamune®, Wyeth, USA) for 21 days at 37 °C and 5% CO₂. IL-2 (1000 IU/mL, Proleukin®, Novartis, UK) was added at day 4 post-activation and replenished every 2 days. Cells were restimulated with beads every 7 days. After 21 days of culture, beads were magnetically removed and the cells washed in TECSMacs GMP medium. After washings, fresh beads, rapamycin and IL-2 were added. Expanded cells were used for further analysis at each time of re-stimulation up until day 21 of expansion.

Phenotypic characterization
Phenotypic characterization were performed on day 0, 7, 14, 21 of cultures for ex vivo expansion and after cryopreservation/thawing by flow cytometry as above described. Surface marker staining was performed in order to assess the content of Tregs and contaminant cells [monocytes (CD14+), B (CD19+) and T cells (CD8+), NK cells (CD56+), Th17 cells (CD196+CD161+) present at each time point of culture (Additional file 1: Table S1).

Mixed leukocyte reaction assay
The T cells were used as autologous responder cells for in vitro suppression assays. The suppressive activity of freshly isolated and expanded cells were tested by co-culturing CD8−CD25− T cells, labeled with 5 μM carboxyfluorescein succinimidyl ester (CFSE, Invitrogen), with serial dilutions of freshly isolated (CD8−CD25+ T cells) and ex vivo expanded autologous Tregs in the presence of CD3/CD28 GMP beads at ratio previously shown by us (in house experiments) to be effective in dose–response experiments (1:10 CD8−CD25− T cells to bead ratio) in RPMI-1640 medium containing 10% FBS, 1% penicillin/streptomycin and 2% glutamine (1%) for 5 days at 37 °C and 5% CO₂. Proliferation was analyzed by flow cytometry. The percentage of proliferative CD8−CD25− T cells in the absence of Tregs was taken as 100% proliferation.

GMP Treg isolation and expansion for in vivo experiments
The GMP manufacturing was performed in the Cell Factory of Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, certified in compliance with
European GMP regulations by the Italian Drug Agency (authorization number aM-51/2018).

Steady state leukapheresis from 2 patients (1 KT and 1 LT patient) were processed using GMP-compliant devices and reagents (Additional file 1: Figure S1A). The subjects were evaluated for venous accesses suitability. Leukapheresis was carried out by the COM. TEC® (Fresenius Kabi AG, Bad Homburg, Germany) cell separator. The treatment of two blood volumes was set up as the procedure end-point. ACD-A was used for anticoagulation at a ratio of 1:14–1:13. For prophylaxis of citrate-related hypocalcemia, calcium gluconate was administered intravenously during the leukapheresis.

CD8−CD25+ cells were purified using the CliniMACS System (Miltenyi Biotec, Bergisch Gladbach, Germany) according to GMP procedures and following manufacturer’s instructions. Briefly, we performed a sequential two-step process based on the magnetic depletion of CD8+ T cells, followed by a positive selection of CD25+ cells after an over night storage, using monoclonal antibodies anti-CD8 (Miltenyi Biotec) and anti-CD25 (Miltenyi Biotec), as described in the CliniMACS user manual for cell preparation, magnetic labelling, and selection.

Forty millions of CD8−CD25+ cells were expanded in vitro in gas-permeable culture bags (MACS GMP Cell Expansion Bags and MACS GMP Cell Differentiation Bags, Miltenyi Biotec) for 3 weeks in complete medium, consisting of TexMACS Medium (Miltenyi Biotec) supplemented with 100 nM rapamycin (Miltenyi Biotec), 5% allogeneic human heat-inactivated AB plasma, 500–1000 UI/mL IL-2 (Proleneukin, Novartis Pharmaceuticals Canada Inc, Dorval, Quebec, Canada). On day 0, 7 and 14, anti-CD3/CD28 beads (MACS GMP ExpAct Treg Beads, Miltenyi Biotec) were added at different beads:cells ratio 4:1, 1:1, 1:1 respectively.

At day 21 all the cultured cells were collected and the beads were removed using the CliniMACS device, according to manufacturer’s instructions. Cells were counted by an automated and validated method (Nucleocounter System, Chemometec, Allerød, Denmark). The Treg markers were evaluated by flow cytometry (BD FACSCanto II, BD Bioscience, San Jose, CA, USA) using the following antibodies: CD45 APC-H7 (BD Bioscience), CD4 FITC (BD Bioscience), CD25 APC (BD Bioscience), CD127 PE-Cy7 (BD Bioscience) and FoxP3 PE (eBioscience, San Diego, CA, USA).

Negative fraction (CD8−CD25− T cells) after GMP selection at day 0 and the final product after GMP expansion at day 21, were cryopreserved and thawed as above described.

Cryopreservation and thawing of freshly isolated and expanded cells

Freshly isolated fractions (CD8−CD25+ and CD8−CD25− T cells) and expanded cells (after 7, 14 and 21 days of expansion) were washed and cryopreserved with 10% DMSO (CRYOSERV, Mylan Institutional, Canonsburg, PA, USA), 10% HSA (HAS; Kedrion, Lucca, Italy) in a saline solution (B. Braun, Melsungen, AG, Germany) using a controlled-rate freezer. The frozen units were transferred and stored immediately to vapor-phase liquid nitrogen into dedicated tanks. All the cellular fractions were thawed at 37 °C and the viability, phenotype and suppressive function were assessed as above described.

Xenogeneic GVHD mouse model

NOD scid gamma (NSG) female mice (6–7 weeks of age) were purchased from Charles River (Calco, Italy). All animals were housed under specific pathogen-free conditions in compliance with guidelines of the San Raffaele Institutional Animal Care and Use Committee (IACUC number: 632). Mice were maintained for at least 5 days in the animal facility for acclimatization before transplantation. To promote the engraftment of transplanted cells injected intraperitoneally, all mice were conditioned with total body irradiation (1.75 cGy) on day 1. Of note, day 1 of the study is considered the day of transplant. All groups of mice, transplanted as well as control mice, were monitored for 7 weeks. Clinical signs of GVHD (e.g., hunched back, fur loss, skin inflammation) were monitored daily. Body weight was monitored throughout the duration of the study. Animals showing marked clinical signs as of distress, loss of weight equal to or greater than 20% of their starting weight were immediately sacrificed.

Xenogeneic GVHD mouse model

To establish whether the expanded Tregs could counteract acute GVHD, a xeno-GvHD model was induced by intraperitoneally transfer of human autologous CD8−CD25− T cells from 1 LT and 1 KT patient into mice. Both CD8−CD25− T cells and expanded Tregs were injected within 30 min from thawing (Additional file 1: Figure S1B). Specifically, human CD8−CD25− T cells (6 × 10⁶) from LT or KT patients were injected with (simultaneous injection) or without autologous Treg (6 × 10⁶) at a Treg: CD8−CD25− T cells ratio of 1:1. Timing of Treg infusion is crucial. In our model Tregs were infused at the time of T effector transplantation.

In vivo engraftment monitoring

To assess the in vivo persistence of human cells, transplanted mice were bled 4 weeks after transplantation and sacrificed 7 weeks after transplantation. Phenotype analysis of injected cells and of peripheral blood at 4 weeks (± 3 days) after transplantation and of PB and spleen at
7 weeks (±3 days) after transplantation was performed (Additional file 1: Figure S1C). Following a Fc blocking step, cell surface staining was performed with anti-mouse CD45 and anti-human CD4, CD3, CD25, FoxP3 mAbs at 1:100 dilution in staining buffer (PBS, 2% FCS, 0.1% NaCl) (list of mAbs is in Additional file 1: Table S1). To detect FoxP3, cells were treated and stained with the FoxP3 fixation/permeabilization kit according to the manufacturer’s instructions (eBioscience). Samples were acquired on a BD FACSCanto II flow cytometer. Manual analysis of flow cytometry data was performed with FCS Express V4 (DeNovo Software, Glendale, CA).

Statistical analyses
Statistical analyses were performed using GraphPad Prism (GraphPad Prism 5.0 software, San Diego, CA, USA), and data are presented as mean ± standard error of the mean (SEM). For all experiments involving multiple comparisons, analysis of variance (ANOVA) followed by a Dunnett’s post hoc test was used. For those who involved comparisons between two groups, Student’s t-test was used. The level of significance was set at p ≤ 0.05.

Results
Enumeration of circulating Treg from LT and KT patients
We firstly enumerated circulating CD4+CD25+CD127−FoxP3+ Tregs in End-Stage Organ Disease patients and controls. The mean absolute numbers of circulating Tregs from LT (19.8 ± 10^5/mL) and KT (18.8 ± 7/mL) patients was not significantly different from that of healthy controls (17 ± 4/mL) (p = NS; Additional file 1: Figure S2).

Tregs isolation, expansion, cryopreservation and thawing
Starting from 60 mL of PB (patients) and 30 mL of buffy-coat (healthy controls), CD8 depletion with subsequent CD25+ enrichment of PBMCs yielded a median of 3.7 × 10^6 nucleated cells (range 1.28–8.8 × 10^6) in healthy controls, 1.47 × 10^6 nucleated cells (range 5.3 × 10^5–2.56 × 10^6) in LT patients and 1.77 × 10^6 nucleated cells (range 8.5 × 10^5–2.7 × 10^6) in KT patients. The freshly isolated CD8−CD25+ T cells were 2.0 ± 1.2, 1.9 ± 1.3 and 2.6% ± 0.7 of the PBMCs, respectively, with no significant differences between patients/controls (p = NS) (data not shown). The Fig. 1a shows the gating strategy for identification of CD4+CD25+CD127−FoxP3+ Tregs which represented more than 80% of the cells (range 70–96%) within the CD8−CD25+ population. The median Treg purity (CD4+CD25+CD127−FoxP3+ cells) was 72% (range 50–84) and 55% (range 40–70) in LT and KT patients, respectively and 65% (range 54–80) in healthy controls (Fig. 1b). No significant difference was observed between patients and controls (p = NS). On day 0, contaminating cells in healthy controls were CD19+ B cells (16%, range 14.8–17), Th17 cells (4.7%, range 0.7–6.9) and CD14+ monocytes (6.3%, range 0.8–11.4). In LT and KT patients, contaminating cells were mainly CD19+ B cells (6.8%, range 1.1–8.4; 5.4%, range 1.9–8.9, respectively) and Th17 cells (7.3%, range 1.4–12.8; 11.8%, range 10.3–13.3, respectively). Natural Killer cells and monocytes content was always very low (below 1%) (Fig. 1c). By comparing patients and controls, Th17 cells were significantly increased in KT cells as compared with LT or healthy controls (p ≤ 0.05 vs. LT patients; p ≤ 0.05 vs. healthy controls). In addition, CD19+ cells were significantly reduced in both patient groups as compared with the normal counterparts (p ≤ 0.05 for LT patients; p ≤ 0.05 for KT patients).

After 21 days, Tregs expanded a median of 197-folds (range 26–567) in LT patients, 266-folds (range 233–300) in KT patients and 559-folds (range 342–826) in healthy controls (Fig. 2a). Differences between patients and controls were not statistically significant. Starting from freshly isolated 500 × 10^3 cells, the final yield was a median of 255 × 10^6 (range 171 × 10^6–413 × 10^6) nucleated cells in healthy controls, 48 × 10^6 (range 30 × 10^6–284 × 10^6) nucleated cells in LT patients and 133 (range 116 × 10^6–150 × 10^6) nucleated cells in KT patients (data not shown). Treg purity (CD4+CD25+CD127−FoxP3+) increased significantly during expansion (Fig. 2b) in healthy donors and KT patients (p ≤ 0.05). Contaminating cells, namely B cells, Th17 cells and monocytes decreased below 1% in healthy controls and LT patients and below 3% in KT patients (Fig. 2c).

When cryopreserved/thawed 21 days expanded Tregs were analyzed, the mean percentage of viable cells was always more than 75% with no significant differences between patients and controls (Fig. 2d). The mean percentage of CD4+CD25+CD127−FoxP3+ cells was always > 80% (Fig. 2e).

When functional assays were performed, freshly isolated cells (CD8−CD25+ T cells) from the three groups exerted a limited (healthy controls and LT patients) or poor (KT patients) suppressive effect toward autologous CD8−CD25− T cells proliferation in vitro (Fig. 3a). After 21 days of in vitro expansion, flow cytometry analysis demonstrated that, according to the increased T regulatory phenotype, Tregs from patients/controls had significant suppressive activity (Fig. 3b), which was not modified by cryopreservation/thawing (Fig. 3c).

All together these data demonstrate that our small scale Treg isolation and expansion protocol from LT and KT patients lead to functional Tregs which are suitable for cell therapy. Moreover, cryopreservation/thawing does not impair phenotype/function of the expanded Tregs.
FOXP3 methylation analysis

Figure 4a shows that in males the locus, which is localized on X chromosome, displayed low DNA methylation values (CpG sites ranging from 0.08 to 0.44). As expected, in females CpG sites had higher methylation values (ranging from 0.24 to 0.73) due to X chromosome inactivation. We evaluated DNA methylation differences at day +21 in freshly isolated and cryopreserved/thawed expanded cells in patients and controls separately using paired t-test. The large majority of CpG sites was not significant, and intra-individual difference between the two groups were generally small, spanning between −0.13 and 0.23. The

Fig. 1 Phenotype of the freshly isolated Tregs. a The gating strategy of Tregs identification after CD8 depletion and CD25 enrichment is shown. Dot plots depict the expression of CD25, CD127 and FoxP3. Interestingly, the majority of the freshly isolated cells expressed CD25. Dot plots are representative of 11 independent experiments from patients/controls. b Graph shows Treg purity, as percentage of CD4+CD25+CD127−FoxP3+ cells after isolation from PB of CTR, LT and KT patients. No significant difference was observed between patients and controls (p = NS). c Graph displays the percentages of contaminant cells in the freshly isolated product from CTR, LT and KT patients. Data are represented as mean ± SEM (*p < 0.05)
Fig. 2  Phenotype of the in vitro expanded Tregs. a Tregs from CTR, LT and KT patients were expanded up to 21 days with IL-2 and rapamycin. Fold expansion of day 7, 14 and 21 was calculated as compared to day 0 seeded cells. b Graph shows the percentage of Treg (CD4+CD25+CD127−FoxP3+) at each time point stimulation. Treg purity increased significantly during expansion in CTR and KT patients. c The graph shows the percentages of contaminant cells during the expansion period. The contaminant cells decreased below 1% in CTR and in LT patients and below 3% in KT patients at the end of expansion. d Viability of cryopreserved/thawed day 21 Tregs is shown. No significant difference was observed between patients and CTR (p = NS). e Phenotype of the cryopreserved/thawed day 21 Tregs is shown as mean percentages of CD4+CD25+CD127−FoxP3+ cells. The thawed Tregs were almost all FoxP3 positive in patients/CTR. No significant difference was observed between patients and controls (p = NS). Data are represented as mean ± SEM (*p < 0.05)
Fig. 3 Suppressive function of the in vitro expanded Tregs. The graphs show the mean percentages of proliferation of the CFSE-labelled autologous CD8−CD25− T cells in the presence of CD3/CD28 GMP beads and Tregs at different ratios. a MLR with freshly isolated Tregs (day 0). Freshly isolated Tregs from the three groups were limited (CTR and LT patients) or very poorly (KT patients) suppressive. b MLR with freshly isolated expanded Tregs (day 21). Expanded Tregs from patients/CTR had significant suppressive activity at 1:2 and 1:4 (Treg:CD8−CD25− T cells) ratio. c MLR with expanded and cryopreserved/thawed day 21 Tregs. Cryopreservation/thawing did not significantly affects the suppressive activity of day 21 expanded Tregs of patients/CTR. Data are represented as mean ± SEM (*p < 0.05, **p < 0.01, ***p < 0.001)

only exception was the CpG_3 among controls (p-value: 0.002), but, also in this case, the difference between the freshly isolated and the cryopreserved/thawed cells was small, ranging from 0.06 to 0.07 (Fig. 4b).

Collectively, these data suggest that the DNA methylation pattern of FOXP3 gene is substantially conserved after cryopreservation/thawing of ex vivo expanded Tregs from LT and KT patients.

In vivo study
To investigate whether GMP expanded Tregs from 1 KT and 1 LT patient have inhibitory function in vivo after thawing, we used a xenograft model of lethal GVHD. Specifically, irradiated NSG mice were injected with cryopreserved/thawed CD8−CD25− T cells either alone or in combination with autologous expanded cryopreserved/thawed Tregs at 1:1 ratio to assess their ability to ameliorate GVHD (Additional file 1: Figure S1). The rationale for this design is that early infusion of Tregs allows the cells to prevent T effector activation. After the immunomagnetic selection and expansion of 40 millions of freshly isolated CD8−CD25+ T cells under GMP condition, we obtained 4.3 × 10^9 total cells (107.1-fold expansion) for the KT patient and 4.6 × 10^9 total cells (115.2-fold expansion) for the LT patient. Before expansion the percentage of CD45+/CD4+/CD25+ cells was 84.9% and 53.9% in KT and LT patient whereas, at the end of expansion, the percentage of CD45+/CD4+/CD25+ cells increased up to 98.3% and 89.2% respectively. At day 21 CD45+/CD4+/CD25+/CD127−/FoxP3+ cells were 79.2% and 84.4% respectively (data not shown).

Tregs were then thawed and characterized for the phenotype and in vitro function. As shown in Fig. 5a, b, the thawed Tregs were more than 80% CD4+CD25+CD127−FoxP3+ and highly suppressive.

Mice receiving KT CD8−CD25− T cells lost weight and all succumbed to GVHD by day 40. In contrast, mice receiving KT CD8−CD25− T cells and autologous Tregs showed delayed disease-associated weight loss and slightly increased survival rate (by day 48 17% of mice receiving CD8−CD25− T cells with Tregs from the KT patient survived versus 0% for mice receiving CD8−CD25− T cells only; p = NS) (Fig. 6a, b). Similar results were obtained with cells from the LT patient: by day 48 58% of mice receiving CD8−CD25− T cells with Tregs from the LT patient survived versus 12.5% for mice receiving CD8−CD25− T cells only (p = NS; Fig. 6c, d).

To assess human cells engraftment in PB, animals were bled after 4/7 weeks and the percentages of human CD45+ cells in blood was determined (Fig. 7). The gating strategy is shown in Fig. 7a. No human CD45+ cells were identified in the PB of mice after infusion of Tregs alone from KT or LT patients. Conversely, a wide distribution of human CD45+ cells was observed in the PB of mice after transplant of CD8−CD25− T cells alone or CD8−CD25− T cells plus Treg infusion (Fig. 7b, c).

To assess the biodistribution of infused human cells, spleen and PB cells of mice were stained with anti-human CD45, CD3, CD4, FoxP3 monoclonal antibodies after 7 weeks from transplant. The gating strategy is shown in Fig. 8a. By comparing PB and spleen, a higher mean percentage of human CD45+ cells was observed in the spleen versus PB of the mice after receiving CD8−CD25− T cells plus Treg of LT patients (p < 0.003; Fig. 8b). Of note, the majority of the human CD45+ cells were CD3+CD4+ in the blood/spleen of mice.
after receiving KT or LT cells (Fig. 8c). Human FoxP3+ Tregs were identified in the CD3+CD4+ fraction of PB and spleen of the two groups of mice without differences between KT and LT cells (Fig. 8d).

Discussion

The use of Tregs for the treatment of GVHD and for inducing operational tolerance after solid organ transplantation is a promising approach.

Here, we isolated, expanded and functionally characterized Tregs from patients with end stage kidney and liver disease, with the aim to establish a suitable method to obtain immunomodulatory cells for adoptive immunotherapy post-transplantation.

We demonstrated that fully functional Tregs from patients in waiting list for solid organ transplantation can be isolated/expanded for clinical studies. These cellular products show homogenous regulatory T cells characteristics with very low percentage of contaminating cells. Therefore, unwanted immune side effects are minimized. Of note, based on phenotype/function, the isolated/expanded Tregs from KT and LT patients are similar. Interestingly, our cryopreservation/thawing procedure allowed cell suspensions with phenotype/function and hypomethylation of the FOXP3 gene superimposable to that of the freshly isolated counterparts. This finding challenges the notion that cryopreservation of Tregs products is detrimental for their function [25, 26].

Our freshly isolated cells from healthy donors and LT/KT patients showed limited suppressive activity. This is in contrast with previous findings demonstrating 60–80% of suppressive activity by freshly isolated healthy donors cells, which were CD8−CD19−CD25+ cells [22] or CD8−CD25+ cells [27]. However, our results may be due (1) to the low purity of our freshly isolated cell suspension (CD8−CD25+ cells) and (2) to the fact that while our suppressive activity results were based on a 1:2 Treg/
CD8−CD25− T cells working ratio, their ratio was 1:1 Treg/Teff. Whether this results is also due to the fact that our freshly isolated healthy donors cells derive from 24 h aged buffy-coats remains a matter of speculation.

Safinia et al. [10] firstly proposed a GMP production protocol to expand CD25+−enriched cells from PB in the presence of IL-2 and rapamycin to induce tolerance after liver transplantation. In their 36 days expansion protocol, multiple round of in vitro Treg stimulation were necessary to achieve clinically relevant Tregs number. In our protocol indeed, we obtained fully functional Tregs after 21 days of expansion containing less than 1% of contaminating CD8+ effector cells. Expanded, cryopreserved and thawed Tregs remain hypomethylated at intron 1 of
the FOXP3 locus, confirming their epigenetic stability. Functionally, Tregs showed suppressive function against autologous CD8−CD25− T cells.

Several human Treg products have been tested in animal models. However, previous data of Treg cell infusion in non human primates report conflicts regarding the ability of the infused cells to induce transplant tolerance [28–30]. Thus, we decided to use a mouse model of GVHD in immunodepressed mice [i.e. NOD-SCID-gamma KO (NSG) mice] receiving human effector T cells with or without GMP Tregs to prevent the onset of xenogeneic GVHD. In our mouse model, GMP Tregs from LT or KT patients proved to be safe and showed a trend toward reduced lethality of acute GVHD in vivo. Interestingly, GMP Tregs from LT and KT patients did not induce xenogenic GVHD and did not expand as documented by the absence of Tregs in the PB and spleen of mice after 4 and 7 weeks from transplantation. This is probably due to the lack of human IL-2.

Nevertheless, our data are consistent with previous models of xenogeneic GVHD and Treg infusion. The addition of CD25 expressing cells to human
PBMC showed the amelioration of xenogeneic GVHD, whereas the depletion of all CD25+ cells led to the development of lethal xenogeneic GVHD [31]. Also, in vitro expanded Tregs from human peripheral blood or cord blood were able to ameliorate or suppress xenogeneic GVHD [32, 33]. More recently, it has been reported that the infusion of polyclonal human Tregs improved murine xenogeneic chronic GVHD [34]. In addition, Del Papa et al. [22] used a similar methodology (immune-magnetic Treg isolation and polyclonal expansion in the presence of CD3/CD28 beads, IL-2, and rapamycin for 19 days) achieving a median of 8.5-fold expansion and maintaining FoxP3 expression over the culture period. NSG mice that received human leukemic cells and expanded Tregs with conventional T cells were rescued from leukemia and survived without GVHD. Mice that received leukemic cells plus conventional T cells died of severe GVHD within 70 days.

**Conclusion**

In summary, we demonstrated that expanded/thawed GMP Tregs from two different groups of patients with end-stage organ failure were fully functional in vitro and their infusion was safe and resulted in a trend toward reduced lethality of acute GVHD in vivo. These data further support the expanded/thawed Tregs-based adoptive immunotherapy in solid organ transplantation.

**Additional file**

**Additional file 1:** Table S1. Antibodies for flow cytometry. Figure S1. Design of the in vivo study. A. Steady state leukapheresis from 2 patients (1 KT and 1 LT patient) were processed using GMP-compliant devices and reagents. Tregs positive fraction (CD8−CD25+ cells) was purified using the CliniMACS System. Forty millions of CD8−CD25+ cells were...
expanded in vitro for 3 weeks. At day 21 all the cultured cells were collected and the beads were removed using the CliniMACS device, according to manufacturer’s instructions. Negative fraction (CD8−CD25− T cells) after GMP selection at day 0 and the final product after GMP expansion at day 21 were cryopreserved and thawed as described in "Materials and methods" section. B. Irradiated NSG mice were infused with the KT or the LT CD8−CD25− T cells, either alone or in combination with autologous expanded Tregs at 1:1 ratio, to assess their ability to ameliorate GvHD. C. Mice were bled 4/7 weeks after transplantation and sacrificed 7 weeks after transplantation. FACS analysis of the injected cells (day 1), of PB (4 weeks ± 3 days after transplantation) and of PB and spleen (7 weeks ± 3 days after transplantation) was performed. Figure S2. Circulating Tregs in KT and LT patients. Mean absolute number of circulating CD4+CD25+CD127−FoxP3+ Tregs from healthy controls and selected LT and KT patients (p = NS).

Abbreviations
Tregs: regulatory T cells; KT: kidney transplantation; LT: liver transplantation; GMP: good manufacturing practice; aGvHD: acute graft-versus-host disease; GvHD: graft-versus-host disease; IS: immunosuppressive; PB: peripheral blood; WBC: white blood cell; EDTA: ethylenediaminetetraacetic acid, PBMC: peripheral blood mononuclear cells; TSDR: Treg-specific demethylation region; CFSE: carboxyfluorescein succinimidyl ester; RPMI: Roswell Park Memorial Institute; FBS: fetal bovine serum; ACD: acid citrate dextrose; DMSO: dimethyl sulfoxide; HSA: human serum albumin; NSG: NOD scid gamma.

Acknowledgements
Not applicable.

Authors’ contributions
UF and MT contributed equally to this work (first and second Author). CL and RML contributed equally to this work (last and co-last Author). UF and MT design of the study, collection and analysis of data, writing the manuscript; CM, BMG, PC, GP, FC, methylation data collection and analysis, and critical revision of the manuscript; JT, MA BM animal model data generation and analysis and critical revision of the manuscript; MT, LC, VM, BS, GR, data collection and analysis in the GMP facility and critical revision of the manuscript; GV apheresis procedure and critical revision of the manuscript; SD, CA and AM, data analysis; and interpretation; CG, BV, LMG, CM, PAD, providing samples from patients/controls and critical revision of the manuscript; CL and RML, design of the study, writing the manuscript, and providing funding. All authors read and approved the final manuscript.

Funding
This work was supported by a grant from the Italian Ministry of Health (RF-2011-02346763 to RML).

Availability of data and materials
All data generated or analysed during this study are included in this article and its Additional file.

Ethics approval and consent to participate
Patients/controls provided written informed consent and the study was approved by the local ethical committee (232/2015/O/Tess by Investigation Drug Service, Azienda Ospedaliero-Universitaria di Bologna).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology “L. e A. Seràgnoli”, University of Bologna, Bologna, Italy.
2 Cell Factory, Unit of Cellular Therapy and Cryobiology, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milan, Italy.
3 Diabetes Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.
4 Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
5 Nephrology Dialysis and Renal Transplant Unit, Department of Experimental Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
6 Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
7 EPIGET LAB, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
8 IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
9 Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institutet at Huddinge University Hospital, Stockholm, Sweden.
10 Laboratory of Cell Biology, Rizzoli Orthopaedic Institute, Bologna, Italy.
11 Unit of Bologna, CNR Institute of Molecular Genetics, Bologna, Italy.
12 Center for Applied Biomedical Research (CRBA), St. Orsola-Malpighi University Hospital, Bologna, Italy.
13 Azienda Ospedaliero-Universitaria di Bologna S. Orsola-Malpighi, Bologna, Italy.
14 Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, Genoa, Italy.
15 IRCCS Ospedale Policlinico S. Martino, Genoa, Italy.

Received: 19 March 2019 Accepted: 27 July 2019
Published online: 05 August 2019

References
1. Dantal J, Campone M. Daunting but worthy goal: reducing the de novo cancer incidence after transplantation. Transplantation. 2016;100:2569–83.
2. Katabathina V, Menias CD, Pickhardt P, Lubner M, Prasad SR. Complications of immunosuppressive therapy in solid organ transplantation. Radiol Clin North Am. 2016;54:303–19. https://doi.org/10.1016/j.rcl.2015.09.009.
3. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell. 2008;133:775–87. https://doi.org/10.1016/j.cell.2008.05.009.
4. Kawai K, Uchiyama M, Hester J, Wood K, Issa F. Regulatory T cells for tolerance. Hum Immunol. 2017. https://doi.org/10.1016/j.humimm.2017.12.013.
5. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development and function. Annu Rev Immunol. 2003;21:1071–113.
6. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4:330–6.
7. van Maurik AV, Herber M, Wood KJ, Jones ND. Cutting edge: CD4+CD25+Foxp3 regulatory T cells: serious contenders in the promise for immunological tolerance. Blood. 2007;109:837–35.
8. Safinia N, Scotta C, Vaikunthanathan T, Lechler RI, Lombardi G. Regulatory T cells: serious contenders in the promise for immunological tolerance in transplantation. Front Immunol. 2015;6:438. https://doi.org/10.3389/fimmu.2015.00438.
9. Romano M, Tung SL, Smyth LA, Lombardi G. Treg therapy in transplantation: a general overview. Transpl Int. 2017;30:745–53. https://doi.org/10.1111/tri.12909.
10. Brunstein CG, Miller JS, Cao Q, McKenna DH, Hippen KL, Curtisinger J, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood. 2011;117:1061–70. https://doi.org/10.1182/blood-2010-07-297975.
11. Brunstein CG, Miller JS, McKenna DH, Hippen KL, DeFeo TE, Sumstad D, et al. Umbilical cord blood-derived T regulatory cells to prevent CD4+ T-cell-mediated graft rejection: implications for anti-CD154 immunotherapy. J Immunol. 2002;169:5401–4.
12. Lin CY, Graca L, Cobbold SP, Waldmann H. Dominant transplantation tolerance impairs CD8+ T cell function but not expansion. Nat Immunol. 2002;3:1208–13.
13. Golshayan D, Jang S, Tsang J, Garin MI, Mottett C, Lechler RI. In vitro-expanded donor alloantigen-specific CD4+CD25+ regulatory T cells promote experimental transplantation tolerance. Blood. 2007;109:837–35.
14. Marek-Trzonkowska N, Myśliwiec M, Dobyszuk A, Grabowska M, Techmaniska I, Jucinska J, et al. Administration of CD4+CD25highCD127− regulatory T cells preserves β-cell function in type 1 diabetes in children. Diabetes Care. 2012;35:1817–20. https://doi.org/10.2337/dc12-0038.
15. Marek-Trzonkowska N, Myśliwiec M, Iwaszkiewicz-Grazel G, Gliwiński M, Derkowska I, Zalińska M, et al. Factors affecting long-term efficacy
of T regulatory cell-based therapy in type 1 diabetes. J Transl Med. 2016;14:332.

16. Martelli MF, Di Ianni M, Ruggeri L, Falzetti F, Carotti A, Terenzi A, et al. HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse. Blood. 2014;124:638. https://doi.org/10.1182/blood-2014-03-564401.

17. Di Ianni M, Olioso P, Giancola R, Santarone S, Natale A, Papalinetti G, et al. Tregs-protected donor lymphocyte infusions: a new tool to address the graft-versus-leukemia effect in the absence of graft-versus-host disease in patients relapsed after HSCT. Int J Hematol. 2017;106:860. https://doi.org/10.1007/s12185-017-2292-3.

18. Todo S, Yamashita K, Goto R, Zaitus M, Nagatsu A, Oura T, et al. A pilot study of operational tolerance with a regulatory T-cell-based cell therapy in living donor liver transplantation. Hepatology. 2016;64:632–43. https://doi.org/10.1002/hep.28459.

19. Tang Q, Vincenti F. Transplant trials with Tregs: perils and promises. J Clin Invest. 2017;127:2505–12. https://doi.org/10.1172/JCI90598.

20. McKenna DH Jr, Sumstad D, Kadidlo DM, Bardorf B, Lord CJ, Merkel SC, et al. Optimization of cGMP purification and expansion of umbilical cord blood-derived T-regulatory cells in support of first-in-human clinical trials. Cytotherapy. 2017;19:250–62. https://doi.org/10.1016/j.jcyt.2016.10.011.

21. Florek M, Schneidawind D, Pierini A, Baker J, Armstrong R, Pan Y, et al. Freeze and thaw of CD4+CD25+Foxp3+ regulatory T cell results in loss of CD62L expression and a reduced capacity to protect against graft-versus-host disease. PLoS ONE. 2015;10:e0145763. https://doi.org/10.1371/journal.pone.0145763.

22. Del Papa B, Ruggeri L, Urbani E, Baldoni S, Cecchini D, Zei T, et al. Clinical-grade expanded regulatory T cells prevent graft-versus-host disease while allowing a powerful T cell-dependent graft-versus-leukemia effect in murine models. Biol Blood Marrow Transplant. 2017;23(11):1847–51. https://doi.org/10.1016/j.bbmt.2017.07.009.

23. Baron U, Floess S, Wieczorek G, Baumann K, Grützkau A, Fry LJ, et al. A rapamycin-based GMP-compatible process for the isolation and expansion of regulatory T cells for clinical trials. Mol Ther Methods Clin Dev. 2018;8:198–209. https://doi.org/10.1016/j.omtm.2018.01.006.

24. Bashuda H, Kimikawa M, Seino K, Kato Y, Ono F, Shimizu A, et al. Renal allograft rejection is prevented by adoptive transfer of anergic T cells in nonhuman primates. J Clin Invest. 2005;115:1896–902.

25. Ma A, Qi S, Song L, Hu Y, Dun H, Massicotte E, et al. Adoptive transfer of CD4+CD25+ regulatory cells combined with low-dose sirolimus and anti-thymocyte globulin delays acute rejection of renal allografts in Cynomolgus monkeys. Int Immunopharmacol. 2011;11:618–29. https://doi.org/10.1016/j.intimp.2010.11.001.

26. Golab K, Leveson-Gower D, Wang XJ, Grzanka J, Marek-Trzonkowska N, Krzystyniak A, et al. Challenges in cryopreservation of regulatory T cells (Tregs) for clinical therapeutic applications. Int Immunopharmacol. 2013;16:371–5. https://doi.org/10.1016/j.intimp.2013.02.001.

27. Fraser H, Safinia N, Grageda N, Thirkell S, Lowe K, Fry LJ, et al. A rapamycin-based GMP-compatible process for the isolation and expansion of regulatory T cells for clinical trials. Mol Ther Methods Clin Dev. 2018;8:198–209. https://doi.org/10.1016/j.omtm.2018.01.006.

28. Chakraborty R, Mahendravada A, Perna SK, Rooney CM, Heslop HE, Vera JF, et al. Robust and cost effective expansion of human regulatory T cells in immunodeficient mice. Clin Cancer Res. 2006;12:5520–5.

29. Ma A, Qi S, Song L, Hu Y, Dun H, Massicotte E, et al. Adoptive transfer of CD4+CD25+ regulatory T cells prevents acute rejection of renal allografts in nonhuman primates. J Transplant. 2016;14:332.

30. Hannon M, Lechanteur C, Lucas S, Somja J, Seidel L, Belle L, et al. Infusion of clinical-grade enriched regulatory T cells delays experimental xenogeneic graft-versus-host disease induced by autologous T cells in RAG2−/− gammaC−/− immunodeficient mice. Clin Cancer Res. 2006;12:5520–5.

31. Hannon M, Lechanteur C, Lucas S, Somja J, Seidel L, Belle L, et al. Infusion of clinical-grade enriched regulatory T cells delays experimental xenogeneic graft-versus-host disease induced by autologous T cells in RAG2−/− gammaC−/− immunodeficient mice. Clin Cancer Res. 2006;12:5520–5.

32. Huynh V, Le Maux K, Dunlop N, Verin T, Warzocha K, Verheyden O, et al. CD127 analysis of CG dinucleotide methylation using mass spectrometry. Bioinformatics. 2009;25:2164–70. https://doi.org/10.1093/bioinformatics/btp582.

33. Peters JH, Freijers FW, Woestenknik R, Hilbrands LB, Koenen HJ, Joosten I. Clinical grade Treg: gMP isolation, improvement of purity by CD127 depletion, Treg expansion, and Treg cryopreservation. PLoS ONE. 2008;3:e3161. https://doi.org/10.1371/journal.pone.0003161.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.